Analysts think ACET stock price could increase by 1382%
Dec 11, 2025, 12:26 PM
0.00%
What does ACET do
Adicet Bio, based in Boston, develops allogeneic gamma delta T cell therapies for cancer, with its lead candidate ADI-001 targeting CD20 for autoimmune diseases and lymphoma. The company went public on January 26, 2018, and employs 143 people.
7 analysts think ACET stock price will increase by 1381.75%. The current median analyst target is $8.16 compared to a current stock price of $0.55. The lowest analysts target is $5.05 and the highest analyst target is $9.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.